What is the appropriate management for a 1.6 cm branch‑duct intraductal papillary mucinous neoplasm (previously 0.8 cm three months ago) with a CA 19‑9 level of 37 U/mL?

Management of Rapidly Growing Branch-Duct IPMN with Borderline CA 19-9

This patient requires urgent surgical evaluation given the rapid cyst growth rate of 8 mm over 3 months (equivalent to 32 mm/year), which far exceeds the ≥5 mm/year threshold that constitutes a relative indication for surgery, combined with a borderline elevated CA 19-9 at the threshold of 37 U/mL. 1

Critical Risk Assessment

Growth Rate Analysis

• The documented growth from 0.8 cm to 1.6 cm represents a doubling in size over just 3 months, translating to approximately 32 mm/year 1
• Growth rate ≥5 mm/year is associated with a 20-fold higher risk of malignant progression and a 45% 5-year risk of developing malignancy in BD-IPMN <30 mm 1
• This patient's growth rate of 32 mm/year is more than 6 times the threshold for surgical consideration 1

CA 19-9 Significance

• CA 19-9 at 37 U/mL (the exact threshold) has a positive predictive value of 74% and diagnostic accuracy of 81.7% for invasive IPMN 1
• This level qualifies as a relative indication for surgery according to European guidelines 1
• The CA 19-9 must be interpreted in the absence of jaundice or biliary obstruction, which can falsely elevate this marker 1, 2

Multiple Relative Indications Present

This patient has at least TWO relative indications for surgery (rapid growth rate and borderline CA 19-9), which significantly increases malignancy risk and warrants surgical referral 1, 2

Immediate Diagnostic Workup Required

High-Quality Cross-Sectional Imaging

• Obtain dedicated pancreatic protocol MRI with MRCP immediately to assess for absolute indications for surgery 2
• Specifically evaluate for:
  • Enhancing mural nodules ≥5 mm (absolute indication) 1
  • Main pancreatic duct diameter ≥10 mm (absolute indication) 1
  • Main pancreatic duct diameter 5-9.9 mm (relative indication) 1
  • Solid mass or solid component (absolute indication) 1
  • Enhancing mural nodules <5 mm (relative indication when combined with other factors) 1

Endoscopic Ultrasound with FNA

• EUS-FNA is strongly recommended given the presence of multiple worrisome features (rapid growth and elevated CA 19-9) 2
• EUS has superior sensitivity (73-85%) and specificity (71-100%) for detecting mural nodules ≥5 mm compared to other imaging modalities 1
• Cytology positive for high-grade dysplasia or malignancy is an absolute indication for surgery 1
• The combination of borderline CA 19-9 with another risk factor markedly increases malignancy risk, making tissue diagnosis critical 2

Clinical Assessment

• Evaluate for symptoms that constitute relative indications:
  • New-onset diabetes mellitus 1
  • Acute pancreatitis caused by IPMN 1
  • Jaundice (absolute indication if present) 1
  • Abdominal pain or weight loss 3, 4

Surgical Decision Algorithm

Proceed to Surgery If:

1. Any absolute indication is identified on imaging or cytology:

   • Main pancreatic duct ≥10 mm 1
   • Enhancing mural nodule ≥5 mm 1
   • Solid mass 1
   • Jaundice 1
   • Cytology positive for malignancy or high-grade dysplasia 1

2. Multiple relative indications are present (already confirmed in this case):

   • Growth rate ≥5 mm/year (this patient has 32 mm/year) 1
   • CA 19-9 >37 U/mL (this patient is at threshold) 1
   • Additional relative indications if found: MPD 5-9.9 mm, symptoms, mural nodule <5 mm 1

Surgical Approach

• Oncologic resection with standard lymphadenectomy is the preferred procedure for IPMN with absolute indications 1
• Frozen section analysis of pancreatic resection margins should be performed routinely 1
• Five-year disease-free survival after resection is approximately 96%, though surgery carries significant morbidity 1, 2

Critical Pitfalls to Avoid

Do Not Delay Evaluation

• The extremely rapid growth rate (doubling in 3 months) suggests aggressive biology and requires urgent assessment, not routine surveillance 1
• Even small BD-IPMNs can harbor malignancy, and the predictive value improves when multiple features are considered together 2, 5

Ensure Proper CA 19-9 Interpretation

• Confirm absence of biliary obstruction or jaundice before attributing CA 19-9 elevation to IPMN 1, 2
• Consider that approximately 10% of the population are Lewis antigen-negative and cannot produce CA 19-9 [@general medical knowledge@]

Multidisciplinary Evaluation Essential

• Patient fitness for surgery, comorbidities, and life expectancy must be assessed 1, 4
• For patients with significant comorbidities, even one relative indication may warrant surgical consideration 1

Post-Surgical Surveillance

• Lifelong surveillance is required even after resection because recurrence can occur in the remnant pancreas 1
• Patients remain at risk for both recurrent IPMN and concomitant pancreatic ductal adenocarcinoma 6, 7

If Surgery Declined or Patient Unfit

• Enhanced surveillance with imaging every 3 months for the first year given the rapid growth kinetics 2, 8
• Any further growth, development of symptoms, or rising CA 19-9 should prompt immediate surgical re-evaluation 1
• Recognize that conservative management carries substantial risk given the documented aggressive growth pattern 1